Login / Signup

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.

Ian E KropSeock-Ah ImCarlos Henrique BarriosHervé R BonnefoiJulie R GralowMasakazu ToiPaul A EllisLuca GianniSandra M SwainYoung-Hyuck ImMichelino De LaurentiisZbigniew NoweckiChiun-Sheng HuangLouis FehrenbacherYoshinori ItoJigna ShahThomas BouletHaiying LiuHarrison MachariaPeter TraskChunyan SongEric P WinerNadia Harbeck
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The primary end point was not met. Both arms achieved favorable IDFS. Trastuzumab plus pertuzumab plus chemotherapy remains the standard of care for high-risk HER2-positive EBC.
Keyphrases